🔗 Visit the ClinicalTrials.gov page for NCT01689870
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. | J Leukoc Biol | 2013 | 1.90 |
| 2 | Pathways and therapeutic targets in melanoma. | Oncotarget | 2014 | 1.17 |
| 3 | Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. | Front Immunol | 2013 | 0.99 |
| 4 | Checkpoint modulation in melanoma: an update on ipilimumab and future directions. | Curr Oncol Rep | 2013 | 0.94 |
| 5 | Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. | J Transl Med | 2013 | 0.85 |
| 6 | Targeting CD8+ T-cell tolerance for cancer immunotherapy. | Immunotherapy | 2014 | 0.81 |
| 7 | New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. | Clin Cancer Res | 2015 | 0.78 |